A Phase 2 Study of Oral Enzastaurin HCl in Patients With Metastatic Colorectal Cancer
Phase 2
19 Years
N/A
19 Years
N/A
Not Enrolling
Both
Colonic Neoplasms
Both
Colonic Neoplasms
Trial Information
A Phase 2 Study of Oral Enzastaurin HCl in Patients With Metastatic Colorectal Cancer
Inclusion Criteria:
- diagnosed with colorectal cancer that is advanced or metastatic (has spread to other
parts of the body); able to visit the doctor's office every 28 days for at least 6
months; able to swallow tablets
Exclusion Criteria:
- women cannot be pregnant or breastfeeding; no history of significant heart disease or
any other significant medical problems as determined by the patient's physician
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Progression free survival
Outcome Time Frame:
baseline to 6 months
Safety Issue:
No
Principal Investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
Investigator Role:
Study Director
Investigator Affiliation:
Eli Lilly and Company
Authority:
Sweden: Medical Products Agency
Study ID:
9098
NCT ID:
NCT00192114
Start Date:
August 2005
Completion Date:
March 2008
Related Keywords:
- Colonic Neoplasms
- Neoplasms
- Colonic Neoplasms
- Colorectal Neoplasms
Name | Location |
|---|
